1104 GMT December 03, 2020
A paper published in Biological Psychiatry showcases how the researchers connected problems in mice with a defective copy of the MEF2C gene to issues suffered in real life by patients seen at the Greenwood Genetic Center who also have a defective copy of that gene, medicalxpress.com reported.
Those patients have a rare form of autism called MEF2C haploinsufficiency syndrome. Basically, one of their two MEF2C genes in each cell is nonfunctioning, and the one non-mutated copy of the gene isn't powerful enough to regulate brain development the way it should, said Christopher Cowan, Ph.D., chairman of the Department of Neuroscience, whose lab conducted the study. The result in humans includes an inability to use language to communicate, epilepsy, repetitive movements, low muscle tone and breathing problems.
Cowan said the results of the study raise new prospects for treatment.
"We know the problem. The individuals have half as much MEF2C as they need. So, from a therapy standpoint, I think it opens a lot of interesting doors. We can think about ways to introduce more MEF2C into the brain during critical periods of development," he said.
It's not yet clear when interventions could be effective or if there is a developmental point of no return, he said. However, he noted that most children with this syndrome experience seizures by 20 months old, which could be a trigger for genetic testing and then potential treatment.
Cowan has been studying MEF2C for more than a decade. He'd previously found the MEF2 family is involved in synaptic pruning, the process by which the brain becomes more efficient as it prunes away redundant or irrelevant synaptic connections; this process occurs through young adulthood but is most active in the preschool and elementary school years. He'd also observed a connection to fragile X syndrome, the most common inherited form of autism.